Phase I study shows positive clinical data from dose escalation of CAR T therapy in R/R B-NHL

Soligenix reports positive clinical results from synthetic hypericin compatibility study for CTCL

Soligenix Inc. announced the results of its compatibility study evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma have been published in the Journal of the European Academy of Dermatology & Venereology Clinical Practice.

May 17, 2024

Vol.50 No.20

Clinical Roundup

Kyowa Kirin forms global collaborative with advocacy groups to address unmet needs in cutaneous T-cell lymphoma

Kyowa Kirin published a patient-focused global consensus statement that highlights 12 recommendations for healthcare authorities, policymakers, hospitals, and clinicians to drive positive change for the global cutaneous T-cell lymphoma patient community.

May 17, 2024

Vol.50 No.20

Clinical Roundup

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital, and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas on April 24 in Nature Cancer.

April 26, 2024

Vol.50 No.17

Clinical Roundup

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.

April 19, 2024

Vol.50 No.16

Clinical Roundup

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

April 05, 2024

Vol.50 No.14

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

Phase I study shows positive clinical data from dose escalation of CAR T therapy in R/R B-NHL

YOU MAY BE INTERESTED IN

Soligenix reports positive clinical results from synthetic hypericin compatibility study for CTCL

Kyowa Kirin forms global collaborative with advocacy groups to address unmet needs in cutaneous T-cell lymphoma

HER2-CAR T-cell therapy induces antitumor activity in high-risk sarcomas in phase I trial

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Novel treatment for T-cell leukemias and lymphomas demonstrates promise in preclinical study

FDA approves Abecma for earlier lines of treatment for MM

Renew today!

Subscriber content

Login